In this trial, we investigate a radio-chemotherapy (with Capecitabine/Xeloda®) for locally advanced rectal cancer. This therapy is carried out before the tumor is removed in a surgery and represents the current standard therapy. Locally advanced cancer means that the tumor has spread but has not yet reached other organs. We conduct this trial to investigate the safety, tolerability and efficacyof the active agent regorafenib in combination with the above-described standard therapy.
Regorafenib blocks many enzymes that are on the one hand important for the growth of cancer cells; on the other hand, they facilitate the nourishment of blood vessels. In that way, the development of the tumor is corrupted and cut of its nutrient supply. Moreover, there is evidence, routing from laboratory experiments, that regorafenib has the potential to inhibit the spread of tumor cells and therefore prevents the formation of new tumors. We hope to be able to support the shrinkage of the tumor by adding regorafenib to the standard therapy, in order to improve chances to completely remove the tumor in a surgery.